Gan Ning, Jia Tong-le, Tian Nan, Liu Si-Si, Cao Shan
Ning Gan, Department of Neurosurgery, Baoding First Central Hospital, Baoding, Hebei, 071000, China.
Tong-le Jia, Department of Neurosurgery, Baoding First Central Hospital, Baoding, Hebei, 071000, China.
Pak J Med Sci. 2023 Mar-Apr;39(2):434-438. doi: 10.12669/pjms.39.2.6721.
To evaluate the effect of nimodipine combined with atorvastatin calcium on the micro inflammation and oxidative stress levels in patients with cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) and its clinical implications.
A total of 80 patients with CVS caused by SAH who had been admitted to Baoding First Central Hospital from August 2021 to August 2022 were selected and randomly divided into two groups. The control group underwent conventional symptomatic treatment, while the experimental group was administered nimodipine combined with atorvastatin calcium on the basis of conventional treatment. The changes in the micro inflammatory cytokines and oxidative stress factors in the two groups were compared, as well as the differences in clinical efficacy and incidence of adverse drug reactions.
After treatment, the levels of inflammatory cytokines in the experimental group decreased more significantly than those in the control group (p=0.00). After treatment, the serum levels of oxidative stress factors were obviously higher in the experimental group than in the control group (p=0.00). After treatment, the total efficacy was 77.5% in the experimental group and 55% in the control group, and the difference was statistically significant (p=0.04).
Nimodipine combined with atorvastatin calcium could significantly improve the clinical symptoms in patients with CVS after SAH, which would be beneficial, safe, and effective for the patient's recovery.
评估尼莫地平联合阿托伐他汀钙对蛛网膜下腔出血(SAH)后脑血管痉挛(CVS)患者微炎症和氧化应激水平的影响及其临床意义。
选取2021年8月至2022年8月在保定市第一中心医院收治的80例由SAH引起的CVS患者,随机分为两组。对照组采用常规对症治疗,实验组在常规治疗基础上给予尼莫地平联合阿托伐他汀钙。比较两组微炎症细胞因子和氧化应激因子的变化,以及临床疗效和药物不良反应发生率的差异。
治疗后,实验组炎症细胞因子水平下降比对照组更显著(p = 0.00)。治疗后,实验组氧化应激因子血清水平明显高于对照组(p = 0.00)。治疗后,实验组总有效率为77.5%,对照组为55%,差异有统计学意义(p = 0.04)。
尼莫地平联合阿托伐他汀钙可显著改善SAH后CVS患者的临床症状,对患者康复有益、安全且有效。